Viva Biotech Holdings provided unaudited earnings guidance for the six months ended June 30, 2022. For the period, revenue of the Group is expected to increase by over 5% as compared with the corresponding period of last year, of which revenue from the CRO business is expected to increase by over 25%, and revenue from the CDMO business is expected to remain relatively stable; and the Group is expected to record a net loss of not more than RMB 100 million for the Period as compared to the net profit of RMB 95.8 million reported for the six months ended June 30, 2021. Based on the information currently available, the Board considers that the net loss is mainly attributable to (i) the resurgence of COVID-19 in mainland China limiting delivery of the Group's products and services to customers during the Period; (ii) market fluctuation resulting in negative fair value changes in the Group's equity interest in incubation portfolio companies; and (iii) fluctuation of foreign exchange rates during the Period resulting in foreign exchange losses for the Group.